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SLEDAIAbstract Aim of the work: To assess brain abnormalities in neuropsychiatric systemic lupus ery-
thematosus (NPSLE) patients using magnetic resonance imaging (MRI) and to compare the find-
ings to those in SLE patients without neuropsychiatric manifestations as well as to compare
disease activity between SLE patients with and without MRI brain abnormalities.
Patients and methods: The study was conducted on 55 SLE patients (48 female/7 male) with a
mean age of 27.3 ± 4.6 years and disease duration of 4 ± 1.6 years. Patients with NPSLE
(n= 30) and without neuropsychiatric (no-NPSLE) (n= 25) underwent MRI brain. The SLE dis-
ease activity index (SLEDAI), headache disability index andmini mental state score were considered.
Results: Brain abnormalities were detected in 21 SLE patients (38.2%); 16 NPSLE and 5 no-
NPSLE. The brain abnormalities included a significantly higher frequency of white matter changes
in NPSLE (14 patients; 46%) compared to no-NPSLE patients (5 patients; 20%) (p= 0.038). In
NPSLE patients, ischemia was present in 5 patients (16.7%), hemorrhage in 3 (10%) and
encephalopathy in another 3 (10%). The SLEDAI was significantly higher in NPSLE patients with
cognitive impairment(33.6 ± 9.1) and NPSLE patients with headache (24.2 ± 5.6) compared to the
score in no-NPSLE patients (7.2 ± 4.7) (p= 0.001). Patients with MRI brain abnormalities had
significantly longer disease duration (p= 0.03), higher SLEDAI (p= 0.001), mini mental state
score (p= 0.005) and headache score (p= 0.019) than those without. The study revealed an MRI
sensitivity of 0.64.948567;
S8 M.R. Zaky et al.Conclusion: MRI can detect brain abnormalities in SLE patients especially those with NPSLE
and these findings were well correlated with the disease duration, headache score and disease activity.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic
Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Systemic lupus erythematosus (SLE) is a multisystem autoim-
mune rheumatic disease. The clinical manifestations of the dis-
ease are complex, and result from inflammation in a variety of
organs. Although arthritis and skin rash are common present-
ing features, involvement of the central nervous system (CNS)
is often seen. Neuropsychiatric systemic lupus erythematosus
(NPSLE) is a complex neurological disorder and is one of
the most important manifestations of SLE that includes neuro-
logical syndromes of the central, peripheral, and autonomic
nervous system, as well as psychiatric disorders [1–3]. The fre-
quency of NPSLE has been reported in many previous
Egyptian studies to range from 23.3% to 35%. [4–9]. Higher
frequencies were reported in a study from Zagazig (42.9%)
[10] and another from Assiut (46.7%) [11]. In previous studies
from Mansoura the frequency was reported to be 33.3%
[12,13].
The American College of Rheumatology (ACR) has
defined 19 neuropsychiatric syndromes, from headache and
cognitive dysfunction to seizures and psychosis. NPSLE occurs
in 37–95% of patients and are associated with significantly
increased morbidity and mortality. These manifestations can
be the presenting manifestation of SLE or occur at any time
during the disease. Controversy exists concerning the factors
responsible for psychiatric manifestations in these patients,
which have been attributed to pathophysiology of the disease
and psychosocial stressors related to chronic disease
[2,3,14,15].
Routine magnetic resonance imaging (MRI) of the brain is
a first level investigation for evaluation of brain abnormalities.
Many studies discussed the role of MR imaging in the assess-
ment of focal lesions of the brain in patients with NPSLE
[16–20].
The aim of the present work was to assess brain abnormal-
ities in neuropsychiatric SLE patients using MRI and to com-
pare the findings with those in SLE patients without
neuropsychiatric manifestations as well as to compare the dis-
ease activity between SLE patients with and without MRI
brain abnormalities.
2. Patients and methods
Cross-sectional study was conducted including 55 patients
with SLE that fulfilled the diagnosed according to Systemic
Lupus International Collaborating Clinics classification crite-
ria for SLE [21]. Patients were collected from the inpatient
and outpatient clinic of the Rheumatology Department,
Mansoura University Hospital, Mansoura, Dakahlia
governorate, Egypt. Patients with NPSLE (n= 30) who ful-
filled the ACR criteria for neuropsychiatric manifestations
[22] were recruited as well as another 25 SLE patients without
neuropsychiatric manifestations (no-NPSLE). This study wasconducted in accordance with the guidelines of the 1995
Declaration of Helsinki and was approved by the institutional
ethics committee. Informed consent was obtained from
patients.
Disease activity was measured using the SLE disease activ-
ity index (SLEDAI) [23]. The severity of headache was
assessed by headache disability index [24] and the cognitive
impairment was assessed using the mini-mental status
questionnaire [25].
The MR imaging examinations were performed on 1.5
Tesla machine (Symphony, Siemens, Erlangen, Germany) with
the patients in the supine position using head coil. Routine T2,
T1 MR imaging and FLAIR images were done with all
patients and control group. First, a scout sagittal T1 weighted
image was obtained followed by axial T1 weighted images
(TR/TE = 500/14 ms) then axial T2 weighted images
(TR/TE = 4490/86 ms) with FOV of 20–24 cm, matrix size
of 256  256, slice thickness of 5 mm and interslice gap of
1 mm. Image analysis was performed by one neuroradiologist.
The image analysis was performed for the presence of white
matter ischemic changes, area of infarction, presence of hem-
orrhage and area of encephalopathy.
Statistical analysis: All statistical analyses were performed
using Statistical Package for the Social Sciences (SPSS) version
20.0 (SPSS, Chicago, IL). Continuous data were expressed as
mean ± standard deviation (SD), while categorical data were
expressed in number and percentage. The differences among
the groups were determined using a one way analysis of
variance (ANOVA) for continuous data or chi-square test
for categorical data. The comparisons between the patients
with and without brain MRI abnormalities were determined
by independent samples t test. Statistical significance was set
at p< 0.05. Receiver operating characteristic (ROC) curve
was done with calculation of sensitivity, specificity, accuracy
and area under the curve for detection of brain abnormalities
in SLE patients.3. Results
The thirty NPSLE patients were 25 females and 5 males with a
mean age of 27.3 ± 4.6 years. Sixteen patients had cognitive
impairment and 14 had lupus headache. The other 25 patients
(22 females and 3 males) had no-NPSLE with a mean age of
27.3 ± 4.6 years. There is no significant difference in gender
(p= 0.82) and age (p= 0.92) between both groups. The mean
disease duration was comparable among NPSLE patients with
cognitive impairment (4.1 ± 1.8 years), NPSLE patients with
headache (3.9 ± 1.2 years) and no-NPSLE patients
(3.8 ± 1.7 years) (p= 0.08). The mini mental score state of
NPSLE patients was 13.3 ± 3.3) and headache score of
NPSLE patients was 44.4 ± 3.1.
Twenty-one (38.2%) SLE patients revealed MRI brain
abnormalities; 16 had NPSLE and 5 no-NPSLE. The NPSLE
Figure 2 Axial T1-weighted image in a patient with NPSLE
shows hyperintense lesion in the right ganglionic region of recent
intra-cerebral hemorrhage.
Figure 3 Axial T2-weighted image in a patient with NPSLE
shows diffuse hyperintense areas of the white matter denoting
encephalopathy.
Table 1 Magnetic resonance imaging (MRI) findings in
systemic lupus erythematosus (SLE) patients.
MRI findings NPSLE (n= 30) No-NPSLE (n= 25)
White matter changes 14 5
Ischemia 5 –
Hemorrhage 3 –
Encephalopathy 3 –
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of white matter changes compared to no-NPSLE patients (5
patients; 20%) (p= 0.038) (Fig. 1). Patients with NPSLE
revealed ischemia in 5 patients (16.7%), hemorrhage in 3
(10%) (Fig. 2) and encephalopathy in another 3 (10%)
(Fig. 3). No detected abnormalities in the rest of the patients.
Table 1 shows the MR imaging findings in patients with SLE.
The SLEDAI was significantly higher in NPSLE patients
with cognitive impairment (33.6 ± 9.1) and NPSLE patients
with headache (24.2 ± 5.6) compared to the score in no-
NPSLE patients (7.2 ± 4.7) (p= 0.001).
Patients with MRI brain abnormalities had significantly
longer disease duration (4.4 ± 2.1 vs. 3.3 ± 1.5 years respec-
tively, p= 0.03), higher SLEDAI (30.7 ± 9.6 vs. 10.1 ± 8.7
respectively, p= 0.001), higher mini mental state score (14.9
± 2.6 vs. 10.5 ± 2.6 respectively, p= 0.005) and higher head-
ache score (46.3 ± 2.7 vs. 41.3 ± 1.2 respectively, p= 0.019)
than those without.
The ROC curve revealed that MRI has a sensitivity of 0.64,
positive predictive value of 0.76, negative predictive value of
0.83 and area under the curve of 0.71 for diagnosis of brain
abnormalities in SLE patients (Fig. 4).
4. Discussion
In this study, MRI brain abnormities were detected in 38.2%
of SLE patients. Patients with normal MRI were less likely
to have neuropsychiatric manifestations. The study revealed
an MRI sensitivity of 0.64, positive predictive value of 0.76,
negative predictive value of 0.83 and area under the curve of
0.71 for diagnosis of brain abnormalities in SLE patients.
Recent studies report a prevalence of neuropsychiatric mani-
festations of 27–80% in adults, and 22–95% in children with
SLE [16–22]. One study reported that the sensitivity and speci-
ficity of MRI in detecting the brain abnormalities in SLE
patients was 30% and 40%, respectively [17]. Another study
reported that 80% of longstanding SLE patients had abnormal
brain MRI [16] and another study added that abnormal MRI
was reported in 47.2% of patients with diffuse NPSLE [18].
In this study, white matter changes were the most common
imaging findings seen in SLE patients being more frequent in
NPSLE. Infarction, hemorrhage and diffuse encephalopathy
were reported in only NPSLE patients. One study reported
that small vessel disease was the most common (55.6%), fol-
lowed by large vessel disease (13%) and inflammatory-likeFigure 1 Coronal fluid-attenuated inversion recovery (FLAIR)
image in an SLE patient showing multiple periventricular hyper-
intense areas of white matter changes.
MRI: magnetic resonance imaging, NPSLE: neuropsychiatric
systemic lupus erythematosus. NB: White matter changes were
associated with other MRI abnormalities in NPSLE.lesions (6.5%). The most frequent small vessel disease findings
were white matter hyperintensity (53.7%), atrophy (18.5%),
micro bleeds (13.7%) and lacunes (11.1%) [19]. Another study
added that the most common MRI brain abnormality in
NPSLE patients was white matter hyperintensities (57.1%)
associated with gray matter hyperintensities (30.8%),
parenchymal defects (23.3%), and atrophy (15%) [20]. The
brain lesions in SLE are predominantly seen in the periventric-
ular and subcortical white matter, histologically, small lesions
are due to small infarcts with loss of axons and myelin; and
Figure 4 Receiver operating characteristics curve shows the
magnetic resonance imaging (MRI) sensitivity (0.64), positive
predictive value (0.76), negative predictive value (0.83) and area
under the curve is 0.71 for detection of brain abnormalities in SLE
patients.
S10 M.R. Zaky et al.extensive white matter lesion are due to edema or confluent
small lesions in NPSLE [20–24].
Cognitive impairment occurs in 11–50% of SLE patients in
the form of decline in one or more of simple attention, complex
attention, memory, visual spatial processing, language, psy-
chomotor speed and executive function. It is possible that these
cognitive disturbances may be attributed to decreased white
matter integrity, the presence and extent of white matter
lesions, or gray matter damage. Some studies, have found an
association between increased global SLE disease activity
and neuropsychiatric manifestations. This association is prob-
ably more robust for diffuse rather than focal neuropsychiatric
events [26–29].
In this study, the headache score of NPSLE patients was
significantly higher than in those with no-NPSLE
(p= 0.001). Previous study reported that primary headaches
were more prevalent in SLE patients than in healthy subjects
(82% vs. 69%, p= 0.01) [30]. Another study added that head-
ache is frequent in SLE, but, it is not associated with global
disease activity or specific autoantibodies. The majority of
headaches resolve over time, independent of lupus-specific
therapies [31]. Other studies found no association between
migraine and SLE disease activity, biochemical or immunolog-
ical markers and cerebral white matter hyperintensities [32,33].
In this study, patients with abnormal MRI brain had signif-
icantly longer disease duration and higher SLEDAI score, mini
mental state score and headache disability scores than patients
with no MRI brain abnormalities. It has been recently
reported that MRI abnormalities correlated significantly with
longer disease duration and disease activity [18]. Another study
added that patients who had seizures were more associated
with gray matter hyperintensities than patients with other neu-
ropsychiatric manifestations. Patients with cerebrovascular
disease were more associated with gray matter hyperintensity
and parenchymal defects [20]. Cerebrovascular syndrome cor-
related with large vessel disease (p= 0.001) and micro-bleeds
(p= 0.002), cognitive dysfunction with white matter hyperin-tensity (p= 0.045) and myelopathy with inflammatory-like
lesions (p= 0.02) [19].
There are few limitations of this study. The number of
patients is small and the relation of brain abnormalities to
other clinical manifestations, medications received, laboratory
investigations including inflammatory biomarkers and autoan-
tibodies as well as to a damage index were not included in this
study. Using advanced MRI techniques and devices may help
in a better delineation of the brain abnormalities. Further lon-
gitudinal larger scale studies are recommended to confirm the
present results and to monitor therapeutic response.
In conclusion, MRI can detect brain abnormalities in SLE
patients especially those with NPSLE and these findings were
well correlated with the disease duration, headache score and
disease activity.
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